| The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. | |
| | |
MedLine Citation:
|
PMID: 8959079 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Previous studies have shown that somatostatin analogues such as octreotide and lanreotide are effective in suppressing GH and IGF-I levels in acromegaly, but the mode of administration and the frequency of injections were inconvenient for the patients. We have evaluated the effects of a new slow-release (SR), long-acting formulation of lanreotide, a somatostatin analogue, on clinical, biochemical and safety responses in acromegaly. DESIGN: We studied the effects of SR-lanreotide 30 mg administered intramuscularly twice or three times monthly for 6 months. Ten patients were studied, in whom acromegaly was confirmed by clinical features,mean GH > 5 mU/l, and failure to suppress GH to < 2 mU/l after a 75-g oral glucose load. MEASUREMENTS: Subjective improvement in clinical symptoms of acromegaly was graded and recorded. Any adverse reactions were noted. Plasma GH levels were measured every 10 min for one hour from 08300930h; fasting IGF-I levels were determined at 0830h; GH, glucose and insulin responses to oral glucose loading were measured at 0,30,60,90 and 120 minutes from 0930 to 1130h. Baseline measurements were carried out and repeated at 3 and 6 months. Biliary ultrasonography was performed at baseline and 6 months. RESULTS: GH levels in the 10 patients decreased from 26.8 12.0 (mean SEM) to 12.7 7.0 mU/l at 3 months (P = 0.04) and 9.8 5.0 mU/l at 6 months (P = 0.06). Fasting IGF-I levels decreased from 123.2 27.0 to 73.5 13.0 nmol/l at 3 months (P = 0.01), and increased slightly to 97.4 31.0 nmol/l (P = 0.05) but remained below baseline levels at 6 months. Five patients achieved good control (GH < 5 mU/l) at 3 months. In the remaining 5 patients the dose frequency was increased to every 10 days and one achieved good control. IGF-I levels normalized in 3 and 5 patients at 3 and 6 months, respectively. Fasting insulin levels and peak insulin after an oral glucose load did not change significantly at 3 months but decreased from 11.7 2.0 to 7.8 3.3 mU/l (P = 0.05) and 106.2 24.6 to 53.3 14.3 mU/l (P = 0.04) at 6 months, respectively. There was no significant change in fasting glucose at 3 or 6 months. Most patients reported clinical improvement in acromegalic symptoms. No major adverse events were reported, but mild to moderate gastrointestinal symptoms were recorded after the initial injections. One patient developed asymptomatic gallstones at 6 months. CONCLUSIONS: This slow-release formulation of lanreotide given either twice or thrice monthly was well tolerated, more convenient for patients, effective in controlling and alleviating the symptoms of acromegaly, as well as suppressing GH and IGF-I levels, and had no detrimental effects on carbohydrate tolerance in acromegaly. |
| | |
Authors:
|
M al-Maskari; J Gebbie; P Kendall-Taylor |
Related Documents
:
|
11887179 - Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog... 10611579 - Adult height after growth hormone (gh) treatment for gh deficiency due to cranial irrad... 22959569 - Reoperative sternotomy is associated with increased mortality after heart transplantation. 20703889 - The first 3 months after bcnu wafers implantation in high-grade glioma patients: clini... 1563079 - A prospective examination of octreotide-induced gall-bladder changes in acromegaly. 15807869 - Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-t... 12501879 - A comparison of cefditoren pivoxil and amoxicillin/ clavulanate in the treatment of com... 20684929 - Efficacy of median nerve recurrent branch neurectomy as an adjunct to ulnar motor nerve... 2119979 - Recurrent anterior dislocation of shoulder joint. |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: Clinical endocrinology Volume: 45 ISSN: 0300-0664 ISO Abbreviation: Clin. Endocrinol. (Oxf) Publication Date: 1996 Oct |
Date Detail:
|
Created Date: 1997-01-02 Completed Date: 1997-01-02 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 0346653 Medline TA: Clin Endocrinol (Oxf) Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 415-21 Citation Subset: IM |
Affiliation:
|
Department of medicine, University of Newcastle Upon Tyne, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acromegaly
/
blood,
drug therapy* Adult Aged Antineoplastic Agents / administration & dosage, therapeutic use* Delayed-Action Preparations Female Growth Hormone / blood Humans Injections, Intramuscular Insulin / blood Insulin-Like Growth Factor I / analysis Male Middle Aged Peptides, Cyclic / administration & dosage, therapeutic use* Somatostatin / administration & dosage, analogs & derivatives*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Delayed-Action Preparations; 0/Peptides, Cyclic; 11061-68-0/Insulin; 118992-92-0/lanreotide; 51110-01-1/Somatostatin; 67763-96-6/Insulin-Like Growth Factor I; 9002-72-6/Growth Hormone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure.
Next Document: Insulin-like growth factor-I raises serum procollagen levels in children and adults with Laron syndr...